Investing.com - Financial Markets Worldwide

Guardant Health price target raised to $100 from $72 at TD Cowen on strong growth

Published 30/10/2025, 15:14
Guardant Health price target raised to $100 from $72 at TD Cowen on strong growth
GH
0.66%

Investing.com - TD Cowen raised its price target on Guardant Health (NASDAQ:GH) to $100 from $72 while maintaining a Buy rating following the company’s third-quarter results. The stock is currently trading at $92.79, having already surged 213% over the past year according to InvestingPro data.

The precision oncology company reported sales growth of 34% year-over-year excluding true-ups, significantly outpacing the consensus expectation of 22%.

Guardant360 test volume growth accelerated for the fifth consecutive quarter, while Shield revenues reached $24 million, exceeding analyst expectations of $17 million.

Gross margins also outperformed, coming in approximately 300 basis points ahead of forecasts, demonstrating improved operational efficiency.

The company raised its guidance by more than the amount of the quarterly beat, with TD Cowen noting that "momentum remains strong & many upside levers remain for the GH investment case."

In other recent news, Guardant Health reported impressive third-quarter 2025 earnings, surpassing market expectations. The company achieved an earnings per share (EPS) of -$0.39, significantly better than the anticipated -$0.79, and generated revenue of $265.2 million, exceeding the forecasted $235.64 million. This strong performance led to several analysts raising their price targets for Guardant Health. Canaccord Genuity increased its price target to $100 from $75, maintaining a Buy rating, citing broad-based growth in revenue and volume. BTIG also raised its price target to $100 from $80, noting a 12% top-line beat and an increase in guidance. Wolfe Research adjusted its price target to $90 from $75, highlighting Guardant Health’s advancements in blood-based colorectal cancer screening and other technologies. These developments reflect a positive outlook from analysts following the company’s robust quarterly results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.